A thymus-derived peptide that modulates the immune system, supporting T-cell function, enhancing antiviral responses, and acting as an adjunct in immunotherapy, vaccination, and cancer support protocols.
$124.00
For laboratory research use only. Not for human or animal use or consumption. Not a drug, food, dietary supplement, or cosmetic. Not approved by the FDA for any medical use.
Thymosin Alpha-1 is a naturally occurring 28–amino-acid peptide derived from the thymus gland. It plays a critical role in immune modulation, enhancing the body’s ability to respond to infections, cancer, and vaccines.
Thymosin Alpha-1 works by:
Promoting T-cell maturation and differentiation, enhancing adaptive immunity
Activating dendritic cells and NK cells to strengthen innate immune responses
Modulating cytokine production, balancing inflammatory and anti-inflammatory pathways
Supporting antiviral defense and immune system recovery in immunocompromised or aging individuals
Chronic Viral Infections (Hepatitis B/C): 1.6 mg twice weekly for 6–12 months
Cancer Support: 1.6–3.2 mg, 2–3 times weekly alongside chemotherapy
Immune Deficiency: 1.6 mg twice weekly for 3–6 months
Acute Viral Infections: 1.6 mg daily for 5–10 days (e.g., COVID-19 research protocols)
Vaccine Adjuvant: 1.6 mg administered on the day of vaccination
Generally well-tolerated with minimal side effects
Used in research, clinical, and experimental protocols for immune support
Effects may vary depending on patient age, immune status, and concurrent therapies
Immune-modulating thymic peptide
Viral infections and immune restoration
Cancer support and adjunct therapy
Vaccine response enhancement
Anti-aging and immune resilience
Reviews
There are no reviews yet.